Kaspers GJ - Search Results

1

Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin.

Zwaan CM, Reinhardt D, Jürgens H, Huismans DR, Hählen K, Smith OP, Biondi A, van Wering ER, Feingold J, Kaspers GJ. Zwaan CM, et al. Among authors: kaspers gj. Leukemia. 2003 Feb;17(2):468-70. doi: 10.1038/sj.leu.2402749. Leukemia. 2003. PMID: 12592351 No abstract available.

2

Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia.

Goemans BF, Zwaan CM, Vijverberg SJ, Loonen AH, Creutzig U, Hählen K, Reinhardt D, Gibson BE, Cloos J, Kaspers GJ. Goemans BF, et al. Among authors: kaspers gj. Leukemia. 2008 Dec;22(12):2284-5. doi: 10.1038/leu.2008.147. Epub 2008 Jun 19. Leukemia. 2008. PMID: 18563175 No abstract available.

3

Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia.

Parigger J, Zwaan CM, Reinhardt D, Kaspers GJ. Parigger J, et al. Among authors: kaspers gj. Expert Rev Anticancer Ther. 2016;16(2):137-46. doi: 10.1586/14737140.2016.1129903. Epub 2016 Jan 14. Expert Rev Anticancer Ther. 2016. PMID: 26646091 Free article. Review.

4

In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia.

Klumper E, Pieters R, Kaspers GJ, Huismans DR, Loonen AH, Rottier MM, van Wering ER, van der Does-van den Berg A, Hählen K, Creutzig U, et al. Klumper E, et al. Among authors: kaspers gj. Leukemia. 1995 Nov;9(11):1864-9. Leukemia. 1995. PMID: 7475276

5

Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia.

Klumper E, Giaccone G, Pieters R, Broekema G, van Ark-Otte J, van Wering ER, Kaspers GJ, Veerman AJ. Klumper E, et al. Among authors: kaspers gj. Leukemia. 1995 Oct;9(10):1653-60. Leukemia. 1995. PMID: 7564505

6

Drug combination testing in acute lymphoblastic leukemia using the MTT assay.

Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk I, Hählen K, Van Wering ER. Kaspers GJ, et al. Leuk Res. 1995 Mar;19(3):175-81. doi: 10.1016/0145-2126(94)00126-u. Leuk Res. 1995. PMID: 7700079

7

Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report.

Kaspers GJ, Kardos G, Pieters R, Van Zantwijk CH, Klumper E, Hählen K, de Waal FC, van Wering ER, Veerman AJ. Kaspers GJ, et al. Leukemia. 1994 Jul;8(7):1224-9. Leukemia. 1994. PMID: 8035616

8

Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia.

Pieters R, Kaspers GJ, van Wering ER, Huismans DR, Loonen AH, Hählen K, Veerman AJ. Pieters R, et al. Among authors: kaspers gj. Leukemia. 1993 Mar;7(3):392-7. Leukemia. 1993. PMID: 8445945

9

Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells.

Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJ. Kaspers GJ, et al. Leuk Lymphoma. 1995 Nov;19(5-6):407-16. doi: 10.3109/10428199509112198. Leuk Lymphoma. 1995. PMID: 8590840

10

Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants.

Pieters R, den Boer ML, Durian M, Janka G, Schmiegelow K, Kaspers GJ, van Wering ER, Veerman AJ. Pieters R, et al. Among authors: kaspers gj. Leukemia. 1998 Sep;12(9):1344-8. doi: 10.1038/sj.leu.2401129. Leukemia. 1998. PMID: 9737681

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

437 results

Search Page

Filters